Wipfli Financial Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Wipfli Financial Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$19K	Buy	+124	New	+$18.4K	﹤0.01%	1598

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wipfli Financial Advisors's BHVN Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022: 124 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #1598 among its holdings.

240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Wipfli Financial Advisors held 124 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $19K as of Q3 2022.
Biohaven Pharmaceutical Holding Company Ltd. was a new Wipfli Financial Advisors position in Q3 2022.
Biohaven Pharmaceutical Holding Company Ltd. made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1598 holding.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.